Compare Cipla with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs BIOCON - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA BIOCON CIPLA/
BIOCON
 
P/E (TTM) x 24.3 17.1 142.4% View Chart
P/BV x 2.5 2.6 94.0% View Chart
Dividend Yield % 0.6 0.4 147.6%  

Financials

 CIPLA   BIOCON
EQUITY SHARE DATA
    CIPLA
Mar-19
BIOCON
Mar-18
CIPLA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs6781,188 57.1%   
Low Rs484305 158.6%   
Sales per share (Unadj.) Rs198.268.7 288.4%  
Earnings per share (Unadj.) Rs18.57.6 245.3%  
Cash flow per share (Unadj.) Rs35.014.0 250.4%  
Dividends per share (Unadj.) Rs3.001.00 300.0%  
Dividend yield (eoy) %0.50.1 385.5%  
Book value per share (Unadj.) Rs186.386.3 215.8%  
Shares outstanding (eoy) m805.70600.00 134.3%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x2.910.9 27.0%   
Avg P/E ratio x31.498.9 31.7%  
P/CF ratio (eoy) x16.653.4 31.1%  
Price / Book Value ratio x3.18.6 36.1%  
Dividend payout %16.213.2 122.3%   
Avg Mkt Cap Rs m468,031447,900 104.5%   
No. of employees `00022.66.1 368.3%   
Total wages/salary Rs m28,5659,311 306.8%   
Avg. sales/employee Rs Th7,053.16,705.8 105.2%   
Avg. wages/employee Rs Th1,261.51,514.2 83.3%   
Avg. net profit/employee Rs Th659.1736.9 89.4%   
INCOME DATA
Net Sales Rs m159,71041,234 387.3%  
Other income Rs m4,7662,062 231.1%   
Total revenues Rs m164,47543,296 379.9%   
Gross profit Rs m30,9738,291 373.6%  
Depreciation Rs m13,2633,851 344.4%   
Interest Rs m1,684615 273.9%   
Profit before tax Rs m20,7915,887 353.2%   
Minority Interest Rs m-172213 -80.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,569 363.0%   
Profit after tax Rs m14,9244,531 329.4%  
Gross profit margin %19.420.1 96.4%  
Effective tax rate %27.426.7 102.8%   
Net profit margin %9.311.0 85.0%  
BALANCE SHEET DATA
Current assets Rs m124,26641,486 299.5%   
Current liabilities Rs m37,71521,413 176.1%   
Net working cap to sales %54.248.7 111.3%  
Current ratio x3.31.9 170.1%  
Inventory Days Days9164 141.7%  
Debtors Days Days9594 100.7%  
Net fixed assets Rs m105,19050,661 207.6%   
Share capital Rs m1,6113,000 53.7%   
"Free" reserves Rs m148,51148,808 304.3%   
Net worth Rs m150,12351,808 289.8%   
Long term debt Rs m38,30117,898 214.0%   
Total assets Rs m239,63399,897 239.9%  
Interest coverage x13.310.6 126.2%   
Debt to equity ratio x0.30.3 73.9%  
Sales to assets ratio x0.70.4 161.5%   
Return on assets %6.95.2 134.5%  
Return on equity %9.98.7 113.7%  
Return on capital %11.89.6 122.9%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41012,058 476.1%   
Fx outflow Rs m19,0417,348 259.1%   
Net fx Rs m38,3684,710 814.6%   
CASH FLOW
From Operations Rs m16,9116,621 255.4%  
From Investments Rs m-16,687-6,840 244.0%  
From Financial Activity Rs m-3,487-2,397 145.5%  
Net Cashflow Rs m-3,451-2,612 132.1%  

Share Holding

Indian Promoters % 16.0 40.4 39.6%  
Foreign collaborators % 20.8 20.6 101.0%  
Indian inst/Mut Fund % 12.2 8.4 145.2%  
FIIs % 23.7 10.7 221.5%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 19.9 131.7%  
Shareholders   161,166 109,995 146.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 20, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS